A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus.

Simple item page
dc.contributor.authorNardolillo, AnneMarie*
dc.contributor.authorKane, Michael P
dc.contributor.authorBusch, Robert S
dc.contributor.authorWatsky, Jay
dc.contributor.authorHamilton, Robert A
dc.date.accessioned2023-11-21T20:17:16Z
dc.date.available2023-11-21T20:17:16Z
dc.date.issued2014
dc.description.abstractOBJECTIVE: To assess the real-world efficacy and safety of the first sodium-glucose cotransporter-2 inhibitor, canagliflozin, in the treatment of patients with type 2 diabetes mellitus (T2DM). METHODS: This observational study assessed the efficacy and tolerability of canagliflozin in T2DM patients. Primary study outcomes were changes in HbA1C and weight, and percentage of patients reporting adverse effects of therapy. RESULTS: The study criteria were met by 111 patient records. Baseline patient characteristics were: average age, 59 +/- 9 years; mean duration of T2DM, 11.9 +/- 7.3 years; 57.6% of patients were male; 92.8% were Caucasian; baseline BMI, 38.9 +/- 11 kg/m(2); and mean baseline HbA1C, 7.53 (58.8 mmol/mol) +/- 1.08%. HbA1C and weight were significantly reduced by 0.37% and 4.4 kg, respectively. Adverse effects were reported by 21 patients, and 17 (15.3%) discontinued canagliflozin because of adverse reactions. CONCLUSION: Canagliflozin was generally well tolerated and significantly reduced HbA1C levels and body weight in patients with T2DM when added to a regimen of other anti-hyperglycemic agents.
dc.description.urihttps://doi.org/10.4137/CMED.S18182
dc.description.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179440
dc.identifier.citationNardolillo A, Kane MP, Busch RS, Watsky J, Hamilton RA. A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes. 2014 Sep 17;7:25-30. doi: 10.4137/CMED.S18182. PMID: 25288892; PMCID: PMC4179440.
dc.identifier.issn1179-5514
dc.identifier.other25288892
dc.identifier.urihttps://hdl.handle.net/20.500.14303/402
dc.language.isoen
dc.publisherSAGE Publications
dc.relation.ispartofClinical Medicine Insights. Endocrinology and Diabetes
dc.rightsThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). http://rightsstatements.org/vocab/InC/1.0/
dc.subjectInvokana
dc.subjectSGLT-2 inhibitor
dc.subjectcanagliflozin
dc.subjecttype 2 diabetes mellitus.
dc.titleA clinical perspective of canagliflozin in the management of type 2 diabetes mellitus.
dc.typeArticle
local.departmentprogramDepartment of Pharmacy Practice
Files
Collections
Kane, Michael Publications
Pharmacy Resident Publications